CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company ...Middle East

BEIJING, June 26, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that the Company is planning...

Hence then, the article about casi pharmaceuticals announces plan to submit ind application for cid 103 an anti cd 38 antibody in antibody mediated rejection and receipt of a non binding proposal to acquire entire china business of the company was published today ( Wednesday 26/06/2024 - 11:16 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company )

Also on site :

• Vue Cinema Chain Halts Liquidation Threat From Coca-Cola Bottling Giant After Settling Unpaid Bill
• Belgium corrects US on ‘peace board’ claim
• Numbrix 9 - January 23